Abeona Therapeutics (ABEO) Operating Leases (2019 - 2026)

Abeona Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Operating Leases fell 6.47% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 6.47% YoY), while the FY2025 annual figure was $4.1 million, up 24.74% from the prior year.
• Operating Leases was $3.8 million for Q1 2026 at Abeona Therapeutics, down from $4.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.5 million in Q2 2022 to a low of $3.0 million in Q2 2024.
• Historically, Operating Leases has averaged $4.9 million across 5 years, with a median of $4.1 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Operating Leases jumped 80.75% in 2022, then tumbled 49.48% in 2024.
• A 5-year view of Operating Leases shows it stood at $5.9 million in 2022, then declined by 24.8% to $4.4 million in 2023, then retreated by 25.9% to $3.3 million in 2024, then advanced by 24.74% to $4.1 million in 2025, then slipped by 6.27% to $3.8 million in 2026.
• The last three Operating Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.